---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-25-000059"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:41:49.682479+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Maravai LifeSciences guides 2025 revenue $185M-$205M; Q1 revenue $43M-$45M

## Summary
- Full-year 2025 revenue guidance $185M-$205M; Q1 2025 revenue $43M-$45M.
- Adjusted EBITDA excludes interest ($14-16M), D&A ($50-55M), stock-based comp ($45-50M).
- Fully diluted shares ~256M; capex expected $15M-$20M in 2025.
- Guidance excludes impact of potential new acquisitions or unquantified items.

## SEC filing metadata
- accession: 0001823239-25-000059
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000059/0001823239-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323925000059/mrvi-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-25-000059
- JSON: https://secwatch.observer/filing/0001823239-25-000059.json
- Plain text: https://secwatch.observer/filing/0001823239-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.